Suzhou Novoprotein Scientific (688137) Stock Overview

Novoprotein Scientific Inc. researches, develops, produces, and sells raw materials and technical solutions for bio-pharmaceutical enterprises and research institutions in Asia, Europe, the United States, and Oceania. It offers cytokines, target proteins, mRNA vaccine and drug enzymes, recombinant antibodies, and molecular enzymes and reagents; and gene and cell therapy, molecular research and diagnosis, and SRAS-CoV-2 and SARS-CoV-2 related products, as well as related technical services. The company also provides protein expression and purification, antibody, industrial strain and process development, stable cell line, VLP protein, protein crystallization, protein modification and labeling, MHC I-peptide complex protein preparation, antibody development, mRNA synthesis custom, and vaccine development services. It offers its products and services in the fields of biopharmaceuticals, mRNA vaccines and drugs, in vitro diagnostics, biological drugs, basic research of life sciences, and other areas. The company was founded in 2009 and is headquartered in Suzhou, China.